<div id="readability-page-1"><div> <div> Issued on behalf of GT Biopharma, Inc. , /PRNewswire/ -- Equity Insider News Commentary – The oncology sector's pivot toward platform-based precision therapies has signaled smart money abandoning single-asset risk for companies engineering multiple drugs from validated mechanisms[1]. Antibody-drug conjugate pipelines expanding past 200 clinical candidates demonstrate how platform technologies enable rapid target-swapping while preserving core therapeutic advantages, creating sustainable competitive moats that command premium valuations[2]. This structural shift toward modularity positions companies with proprietary engines to capture multiple therapeutic opportunities simultaneously, benefiting GT Biopharma, Inc. (NASDAQ: GTBP), ADC Therapeutics SA (NYSE: ADCT), Sutro Biopharma, Inc. (NASDAQ: STRO), Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX), and TScan Therapeutics, Inc. (NADSAQ: TCRX). Platform technologies now account for 60% of total pharma pipeline value, with immunotherapies commanding over 45% of cancer drug revenues as investors reward modularity over one-shot bets[1]. Clinical-stage biotechs securing $120 million rounds for ADC linker platforms underscore how capital flows toward companies demonstrating platform versatility, where validated mechanisms can address multiple indications without rebuilding infrastructure, compressing development timelines while multiplying commercial opportunities[3]. GT Biopharma, Inc. (NASDAQ: GTBP), a clinical-stage immuno-oncology company, recently reported advancing its Phase 1 clinical trial of GTB-3650 to Cohort 4, where patients now receive 10μg/kg/day dosing. The company specializes in developing next-generation immunotherapy treatments targeting some of the world's most resistant cancer types through its proprietary natural killer cell engager TriKE platform. GT Biopharma's Phase 1 dose escalation trial evaluates GTB-3650 in patients facing relapsed or refractory blood cancers expressing CD33, particularly acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). These cancers represent exceptionally challenging cases where conventional treatments have either failed completely or provided only temporary benefit before disease returned. The therapy harnesses the patient's natural killer cells, an immune cell type that instinctively identifies and eliminates abnormal cells, directing them to attack cancer specifically. Treatment delivery follows a continuous infusion schedule structured as two-week treatment periods followed by two-week rest intervals, with cycles continuing up to four months depending on individual patient response. &#34;We are highly encouraged by the continued progress of our Phase 1 clinical trial evaluating GTB-3650 in cancer patients, which has now advanced to Cohort 4 at a dose level of 10 µg/kg/day,&#34; said Michael Breen, Executive Chairman and CEO. &#34;We look forward to assessing higher doses, as we are now approaching the efficacy range predicted by preclinical in vivo leukemia models, and we plan to share the next trial update in the first quarter of 2026.&#34; The six patients enrolled throughout Cohorts 1, 2, and 3 have completed GTB-3650 treatment successfully, establishing the therapy's safety profile across escalating dose concentrations. GT Biopharma indicates the current Cohort 4 dose of 10μg/kg/day represents a threshold where clinical efficacy becomes more likely, supported by encouraging immunological biomarker trends and zero dose-limiting toxicities across all completed cohorts. The first-in-human Phase 1 protocol plans for approximately 14 patients distributed across seven cohorts, with each cohort enrolling two patients at progressively increasing doses starting from 1.25μg/kg/day in Cohort 1 and potentially reaching 100μg/kg/day in Cohort 7 if warranted. Following Cohort 4, three additional escalation levels remain: Cohort 5 testing 25μg/kg/day, Cohort 6 evaluating 50μg/kg/day, and Cohort 7 examining the maximum protocol dose of 100μg/kg/day. The company anticipates providing its next comprehensive trial update during first quarter 2026. Beyond hematologic malignancies, GT Biopharma is advancing GTB-5550, targeting B7H3, a protein prevalent across multiple solid tumor categories including breast, lung, ovarian, pancreatic, bladder, and prostate cancers. Regulatory submission to initiate GTB-5550 human trials is expected in late December 2025 or January 2026. Designed as a subcutaneous injection, GTB-5550 offers the potential for eventual self-administration at home, significantly reducing patient burden. Both therapeutic candidates leverage GT Biopharma's proprietary TriKE platform utilizing specialized antibody fragments initially discovered in camels and llamas. These molecules provide distinct advantages compared to traditional antibodies through their compact size and enhanced stability. GT Biopharma maintains exclusive worldwide licensing rights from the University of Minnesota for this technology. CONTINUED… Read this and more news for GT Biopharma, Inc. at: https://equity-insider.com/2025/10/03/the-small-biotech-thats-cracking-the-code-big-pharma-paid-billions-for/ ADC Therapeutics SA (NYSE: ADCT) presented updated data from its LOTIS-7 Phase 1b trial showing ZYNLONTA in combination with glofitamab achieved an 89.8% overall response rate and 77.6% complete response rate across 49 efficacy-evaluable patients with relapsed/refractory diffuse large B-cell lymphoma. The combination demonstrated strong efficacy in both relapsed (100% ORR, 91.7% CR) and primary refractory populations (80% ORR, 64% CR) while maintaining a manageable safety profile with cytokine release syndrome occurring in 36.7% of patients across dose levels. &#34;We're excited that these data continue to demonstrate a manageable safety profile and strong efficacy including deep and durable responses in 2L+ r/r DLBCL patients treated with ZYNLONTA plus glofitamab,&#34; said Mohamed Zaki, MD, PhD, CMO of ADC Therapeutics. &#34;We are well on the way to completing enrollment of approximately 100 patients at the selected dose and plan to share full results at a medical congress and through a publication by the end of next year.&#34; ADC Therapeutics expects to complete enrollment of approximately 100 patients at the selected 150 µg/kg dose during the first half of 2026. The company plans to share full data at a medical meeting and submit for publication by the end of 2026 while assessing regulatory and compendia strategies for this potential best-in-class bispecific antibody-based combination. Sutro Biopharma, Inc. (NASDAQ: STRO) has dosed the first cohort of patients in its Phase 1 trial evaluating STRO-004, a next-generation Tissue Factor-targeting exatecan antibody-drug conjugate designed for enhanced stability, potency, and tumor selectivity. The multicenter trial is assessing safety, pharmacokinetics, and preliminary anti-tumor activity in patients with TF-expressing solid tumors including non-small cell lung cancer, head and neck squamous cell carcinoma, cervical cancer, colorectal cancer, pancreatic ductal adenocarcinoma, and bladder cancer. &#34;Dosing the initial patients in this trial marks an important milestone in bringing forward new treatment options for patients with TF–expressing cancers—many of whom face limited therapy options and difficult prognoses,&#34; said Jane Chung, CEO of Sutro Biopharma. &#34;STRO-004 is engineered to deliver potent, sustained anti-tumor activity and higher exposure compared to approved therapies, with the goal of reaching tumors that are resistant to standard approaches.&#34; The dose-escalation phase features high entry doses supported by strong tolerability in non-human primates at up to 50 mg/kg, with initial clinical data expected in mid-2026. Sutro's proprietary cell-free platform produces STRO-004 with site-specific β-glucuronidase cleavable linker and exatecan payload at a drug-to-antibody ratio of 8, designed to enhance stability and maximize efficacy. Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) dosed the first patient in its Phase 1/2 BRAVESST trial evaluating CRN09682 for neuroendocrine tumors and other somatostatin receptor 2-expressing solid tumors. The investigational nonpeptide drug conjugate represents the lead candidate from Crinetics' proprietary NDC platform, designed to bind selectively to SST2-expressing tumor cells while promoting rapid receptor internalization to release a cytotoxic payload directly within tumors. &#34;We developed CRN09682 to address the need for a more efficacious, safer, and convenient targeted therapy for patients with SST2-expressing tumors,&#34; said Stephen Betz, Ph.D., Chief Scientific Officer and Co-Founder of Crinetics. &#34;Dosing the first patient in the Phase 1/2 study marks a major milestone for CRN09682 and our NDC platform as a whole. CRN09682 is the first clinical exploration of this new modality, which we believe has the potential to unlock a new generation of receptor-targeted therapies to treat tumors with precision.&#34; The first-in-human, open-label trial will enroll up to 150 participants with dose escalation followed by expansion phases evaluating safety, tolerability, pharmacokinetics and preliminary anti-tumor activity. CRN09682 utilizes traditional chemical synthesis methods, eliminating manufacturing constraints required by most antibody drug conjugates and radiopharmaceuticals. TScan Therapeutics, Inc. (NASDAQ: TCRX) announced positive updated data from its ALLOHA Phase 1 trial showing TSC-101 continued to demonstrate favorable relapse-free survival (HR=0.50) and overall survival (HR=0.61) in patients with hematologic malignancies undergoing allogeneic hematopoietic cell transplantation. All three TSC-101-treated patients who reached two-year follow-up remained relapse-free compared to only one of four patients (25%) in the control arm, with no dose-limiting toxicities observed across all dose levels. &#34;These updated data from our Phase 1 study continue to highlight a positive safety and efficacy profile of TSC-101 in patients with heme malignancies undergoing allogeneic HCT,&#34; said Chrystal U. Louis, MD, CMO of TScan Therapeutics. &#34;All three patients who reached two years of follow-up have no detectable disease as they have remained relapse-free and in complete donor chimerism. Additionally, there have been no dose-limiting toxicities and patients who received TSC-101 continue to show improved relapse-free and overall survival compared to control-arm patients.&#34; TScan is focused on enrolling the remaining patients necessary to support its fixed-dosing regimen and expects to initiate a pivotal study in the second quarter of 2026. The company plans to expand its heme program in 2026 with product candidates designed to double the addressable patient population for post-transplant maintenance therapy. Article Sources: https://equity-insider.com/2025/10/03/the-small-biotech-thats-cracking-the-code-big-pharma-paid-billions-for/ CONTACT: Equity Insider [email protected] (604) 265-2873 DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. This article is being distributed by Equity Insider on behalf of Market IQ Media Group Inc. (&#34;MIQ&#34;). MIQ has been paid a fee for GT Biopharma, Inc. advertising and digital media from Creative Digital Media Group (&#34;CDMG&#34;). There may be 3rd parties who may have shares of GT Biopharma, Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ/BAY does not own any shares of GT Biopharma, Inc. but reserve the right to buy and sell, and will buy and sell shares of GT Biopharma, Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved on behalf of GT Biopharma, Inc. by CDMG; this is a paid advertisement, we currently own shares of GT Biopharma, Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. SOURCES CITED: <ol type="1"> <li>https://www.prnewswire.com/news-releases/platform-technologies-drive-211b-surge-in-precision-cancer-treatment-302639367.html</li> <li>https://www.globenewswire.com/news-release/2025/11/20/3191714/0/en/Antibody-Drug-Conjugates-Market-Size-to-Surpass-USD-36-22-Billion-by-2034.html</li> <li>https://www.fiercebiotech.com/biotech/fierce-biotech-fundraising-tracker-25 </li> </ol> Logo - https://mma.prnewswire.com/media/2840019/5690937/Equity_Insider_Logo.jpg <img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMjE5Jk5ld3NJdGVtSWQ9TE41MTY2MSZUcmFuc21pc3Npb25fSWQ9MjAyNTEyMTkwNzU1UFJfTkVXU19VU1BSX19fX19MTjUxNjYx?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMjE5Jk5ld3NJdGVtSWQ9TE41MTY2MSZUcmFuc21pc3Npb25fSWQ9MjAyNTEyMTkwNzU1UFJfTkVXU19VU1BSX19fX19MTjUxNjYx"/></div> </div></div>

ADCT

GTBP

The oncology sector is shifting towards platform-based precision therapies, with smart money moving away from single-asset risk. GT Biopharma, Inc. is advancing its Phase 1 trial of GTB-3650 for blood cancers, reaching Cohort 4 with promising safety and efficacy results. The company's TriKE platform targets resistant cancer types, and future updates are expected in 2026. ADC Therapeutics also reports strong efficacy in its LOTIS-7 trial for lymphoma. Platform technologies now dominate 60% of pharma pipelines, emphasizing modularity and versatility in drug development.

07:55 ET Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines